GlassScriptPhysician profile
Burton A Liebross
NPI 1659350718
$5,579.55
in general payments reported to CMS, 2019-2025
41 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,720 · 2020: $361 · 2021: $1,640 · 2022: $454 · 2023: $863 · 2024: $296 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,353 · Education: $51.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,352.91 |
| Education | $51.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,394.24 | 2021 | |
| Amgen INC. | $704.17 | 2019-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $333.11 | 2021-2025 | |
| Abbott Laboratories | $304.77 | 2023 | Proclaim, Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $248.07 | 2019-2024 | Farxiga |
| Pfizer INC. | $217.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $185.66 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Daiichi Sankyo INC. | $175.11 | 2019-2020 | |
| Amarin Pharma, INC. | $174.06 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $160.02 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $145.05 | 2019-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $129.76 | 2022-2024 | |
| Intuitive Surgical, INC. | $115.46 | 2022 | |
| Novartis Pharmaceuticals Corporation | $113.54 | 2023-2025 | |
| Lilly USA, LLC | $101.79 | 2019-2023 | Mounjaro, Taltz |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Burton Liebross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.